PPAR-γ agonists, as well as PPAR-γ antagonists, can inhibit breast growth depending on type of breast cancer (e.g., estrogen receptor status) [41,42,43,44], which makes investigation of dietary factors and breast cancer challenging. This evidence concerns the gene ESR1 and breast carcinoma.